Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients. Issue 11 (November 2019)

• Record Type: Journal Article
• Authors: Huang, Yu-Pin; Lin, Tzu-Ping; Cheng, Wei-Ming; Wei, Tzu-Chun; Huang, I-Shen; Fan, Yu-Hua; Lin, Chi-Chieh; Huang, Eric Y.H.; Chung, Hsiao-Jen; Kuo, Junne-Yih; Wu, Howard H.H.; Lu, Shing-Hwa; Chang, Yen-Hwa; Lin, Alex T.L.; Huang, William J.S.
• Is Part Of: Journal of the Chinese Medical Association. Volume 82:Issue 11(2019)
• Publication Date: 2019-11
• Subjects: [2]pro-Prostate-specific antigen -- Prostate cancer -- Prostate health index density -- Prostate-specific antigen -- Radical prostatectomy; Medicine -- Periodicals; 610.5
• DOI: 10.1097/JCMA.0000000000000169
• Languages: English
• ISSNs: 1726-4901

Abstract

Abstract : Background: There are models to predict pathological outcomes based on established clinical and prostate-specific antigen (PSA)-derived parameters; however, they are not satisfactory. p2PSA and its derived biomarkers have shown promise for the diagnosis and prognosis of prostate cancer (PCa). The aim of this study was to investigate whether p2PSA-derived biomarkers can assist in the prediction of aggressive pathological outcomes after radical prostatectomy (RP). Methods: We prospectively enrolled patients who were diagnosed with PCa and treated with RP between February 2017 and December 2018. Preoperative blood samples were analyzed for tPSA, free PSA (fPSA), percentage of fPSA (%fPSA), [-2]proPSA (p2PSA), and percentage of p2PSA (%p2PSA). Prostate health index (PHI) was calculated as (p2PSA/fPSA) × √tPSA. Prostate volume was determined by transrectal ultrasound using the ellipsoid formula, and PHI density was calculated as PHI/prostate volume. The areas under the receiver operating characteristic curve were estimated for various PSA/p2PSA derivatives. Aggressive pathological outcomes measured after RP were defined as pathological T3 or a Gleason score (GS) >6 as determined in RP specimens. Results: One hundred and forty-four patients were included for analysis. Postoperative GS was >6 in 86.1% of the patients, and pT stage was T3a or more in 54.2%. Among all PSA- and p2PSA-derived biomarkers, PHI density was the best biomarker to predict aggressive pathological outcomes after RP. The odds ratio of having an aggressive pathological outcome of RP was 8.796 ( p = 0.001). In multivariate analysis, adding %fPSA to base model did not improve the accuracy (area under curve), but adding PHI and PHI density to base model improved the accuracy by 2% and 16%, respectively, in predicting pT3 stage or GS ≥ 7. The risk of pT3 stage or GS ≥ 7 was 20.8% for PHI density <1.125, and 64.6% for PHI density >1.125 (sensitivity: 74.6% and specificity: 88.9%). Conclusion: PHI density may further aid in predicting aggressive pathological outcomes after RP. This biomarker may be useful in preoperative counseling and may have potential in decision making when choosing between definitive treatment and active surveillance of newly diagnosed PCa.